All In Biotech

NDA 020083 · Janssen Pharms

Sporanox

Itraconazole · Oral · Azole Antifungal

NovelPriority review

Last checked: Nov 19, 2026Latest source record: Jul 7, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1992

Sep 11, 1992

Approved uses

2

Original approval plus efficacy supplements

Registered trials

507

27 Phase 3, 40 recruiting

FAERS reports

11,784

10,489 serious, 2,277 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

BOXED WARNING Congestive Heart Failure, Cardiac Effects and Drug Interactions Congestive Heart Failure and Cardiac Effects SPORANOX ® (itraconazole) Capsules should not be administered for the treatment of onychomycosis in patients with evidence of ventricular dysfunction such as congestive heart failure (CHF) or a history of CHF. If signs or symptoms of congestive heart failure occur during administration of SPORANOX ® Capsules, discontinue administration. When itraconazole was administered intravenously to dogs and healthy human volunteers, negative inotropic effects were seen. (See CONTRAINDICATIONS , WARNINGS , PRECAUTIONS: Drug Interactions , ADVERSE REACTIONS: Postmarketing Experience , and CLINICAL PHARMACOLOGY: Special Populations for more information.) Drug Interactions Coadministration of a number of CYP3A4 substrates are contraindicated with SPORANOX ® . Some examples of...

What it is approved for

From the label in effect Jul 13, 2026.

INDICATIONS AND USAGE SPORANOX ® (itraconazole) Capsules are indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: Blastomycosis, pulmonary and extrapulmonary Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy. Specimens for fungal cultures and other relevant laboratory studies (wet mount, histopathology, serology) should be obtained before therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, antiinfective therapy should be adjusted accordingly. SPORANOX ® Capsules are also indicated for the treatment of the following fungal infections in non-immunocompromised patients: Onychomycosis of the toenail, with or without fingernail involvement, due to dermatophytes (tinea unguium), and Onychomycosis of the fingernail due to dermatophytes (tinea unguium). Prior to initiating treatment, appropriate nail specimens for laboratory testing (KOH preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis of onychomycosis. (See CLINICAL PHARMACOLOGY: Special Populations , CONTRAINDICATIONS , WARNINGS , and ADVERSE REACTIONS: Postmarketing Experience for more information.) Description of Clinical Studies Blastomycosis Analyses were conducted on data from two open-label, non-concurrently controlled studies (N=73 combined) in patients with normal or abnormal immune status. The median dose was 200 mg/day. A response for most signs and symptoms was observed within...

Mechanism: Mechanism of Action In vitro studies have demonstrated that itraconazole inhibits the cytochrome P450-dependent synthesis of ergosterol, which is a vital component of fungal cell membranes.

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 29, 1994 Supplement 4 · Efficacy
  • Sep 11, 1992 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
  • SPORANOX · ITRACONAZOLE 100MG · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Itraconazole" as an intervention, any sponsor and status, largest first.

All 507 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug interaction1,191
  • drug ineffective1,144
  • off label use632
  • pyrexia589
  • dyspnoea493
  • pneumonia484
  • nausea468
  • diarrhoea404
  • condition aggravated400
  • febrile neutropenia373
  • fatigue351
  • rash310

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004277
2005192
2006219
2007254
2008291
2009408
2010361
2011621
2012587
2013409
2014373
2015610
2016474
2017517
2018703
2019826
2020868
2021782
2022676
2023676
2024601
2025566
2026492

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Feb 27, 2026

    Sporanox, Capsule, 100 mg (NDC 50458-290-01). Discontinuation of the manufacture of the drug

  • To Be Discontinued · updated Feb 27, 2026

    Sporanox, Capsule, 100 mg (NDC 10147-1700-3). Discontinuation of the manufacture of the drug

  • To Be Discontinued · updated Feb 27, 2026

    Sporanox, Capsule, 100 mg (NDC 50458-290-04). Discontinuation of the manufacture of the drug

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Sporanox (Itraconazole)

2024 spending

$123K

Beneficiaries

26

82 claims

Per beneficiary

$4,730

$12.40 per unit

View as table
YearSpending
2020$509,944
2021$247,250
2022$307,486
2023$196,502
2024$122,988

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 970 on PubMed

Sponsor: Johnson & Johnson (Janssen)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.